Study of Polymorphisms of RAAS and MMPs in Acute Heart Failure

Acute Heart Failure Clinical Trial

— PRA-MMP  

Official title:

Study of Polymorphisms of Renin Angiotensin Aldosteron Systemv(RAAS) and Matrice Metallo Protesase (MMPs) in Acute Heart Failure (AHF)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02170961
• Other study ID #: PRA-MMP
• Status: Completed
• Start date: February 2013
• Est. completion date: December 2016

Study information

• Verified date: August 2020
• Source: University of Monastir
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

this study aim to investigate the:

• association of RAAS polymorphisms and AHF

• association of MMP 3 and 12 polymorphisms and AHF

Description:

Heart failure can be defined as a complex clinical syndrome that results from any structural or functional disorder of the heart, with impairment of ability to fill the ventricles or eject blood. The main event of the IC is dyspnea and fatigue, which limit exercise tolerance and induces water retention.

The renin angiotensin aldosterone system governs the salt and water homeostasis in the body. Renin is a proteolytic enzyme secreted by the juxtaglomerular apparatus of the kidney (area near the glomeruli). Renin has no direct action on the organism, but that is part of the renin-angiotensin system or the renin-angiotensin-aldosterone system is known.

To date, few published studies have examined the association between the polymorphism AGT M235T * and cardiac dysfunction; and available results are contradictory. What is not known yet is the ratio of this polymorphism with the prognosis of heart failure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: December 2016
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• aged more than 18 year old.

• acute non traumatic dyspnea .

Exclusion Criteria:

• ECG diagnostic for acute myocardial infarction or ischemic chest pain within the prior 24 hours

• a history of a heart transplant, pericardial effusion, chest wall deformity suspected of causing dyspnea

• coma, shock,MV,vasopressor drugs

• arrhythmia serious and sustained,

• pace maker

• severe mitral valve disease,

Related Conditions & MeSH terms

• Acute Heart Failure
• Heart Failure

Locations

Country	Name	City	State
Tunisia	Nouira Samir	Monastir	Emergency Department Monastir, Tunisia 5000

Sponsors (1)

Lead Sponsor	Collaborator
University of Monastir

Country where clinical trial is conducted

Tunisia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	mortality RAAS	the association between RAAS genes polymorphisms and mortality at one year average	one year
Secondary	association between RAAS polymorphism and AHF	the association between the diagnosis of AHF (based on clinical, BNP, and echocardiographic finds) and the RAAS genes polymorphism is studied at patient admission for acute dyspnea.	at admission (an average of 1 day)
Secondary	association between MMP polymorphism and AHF	the association between the diagnosis of AHF (based on clinical, BNP, and echocardiographic finds) and the MMP genes polymorphism is studied at patient admission for acute dyspnea.	at admission (average of 1 day)

External Links

•   official website